摘要
背景:阿尔茨海默病(AD)的分子机制尚未完全阐明。所谓的“淀粉状蛋白级联假说”长期以来一直是疾病致因的主流范式,并且现在正在与其他致病途径如氧化应激,神经炎症和能量代谢障碍相关地进行重新研究。过氧化物酶体增殖物激活受体(PPARs)在中枢神经系统(CNS)中表达并调节许多生理过程,如能量代谢,神经传递,氧化还原稳态,自噬和细胞周期。在三种同种型(α,β/δ,γ)中,PPARγ作用是最广泛研究的,而关于α和β/δ的信息仍然很少。然而,最近的体外和体内证据表明PPARα是AD中有希望的治疗靶点。 结论:本综述提供了有关该主题的更新,重点介绍了天然或合成激动剂在AD发作和发作过程中调节发病机制的作用。配体激活的PPARα抑制致淀粉样途径,Tau hyperphosphorylation和neuroinflammation。同时,受体引发对氧化应激的酶抗氧化剂应答,改善葡萄糖和脂质代谢障碍,并刺激自噬。
关键词: 阿尔茨海默病,过氧化物酶体增殖物激活受体,β-淀粉样蛋白,氧化应激,神经炎症,能量代谢,豌豆,贝特类。
Current Alzheimer Research
Title:Targeting PPARalpha in Alzheimer's Disease
Volume: 15 Issue: 4
关键词: 阿尔茨海默病,过氧化物酶体增殖物激活受体,β-淀粉样蛋白,氧化应激,神经炎症,能量代谢,豌豆,贝特类。
摘要: Background: The molecular mechanisms underlying Alzheimer's disease (AD) are yet to be fully elucidated. The so-called “amyloid cascade hypothesis” has long been the prevailing paradigm for causation of disease, and is today being revisited in relation to other pathogenic pathways, such as oxidative stress, neuroinflammation and energy dysmetabolism. The peroxisome proliferator-activated receptors (PPARs) are expressed in the central nervous system (CNS) and regulate many physiological processes, such as energy metabolism, neurotransmission, redox homeostasis, autophagy and cell cycle. Among the three isotypes (α, β/δ, γ), PPARγ role is the most extensively studied, while information on α and β/δ are still scanty. However, recent in vitro and in vivo evidence point to PPARα as a promising therapeutic target in AD.
Conclusion: This review provides an update on this topic, focussing on the effects of natural or synthetic agonists in modulating pathogenetic mechanisms at AD onset and during its progression. Ligandactivated PPARα inihibits amyloidogenic pathway, Tau hyperphosphorylation and neuroinflammation. Concomitantly, the receptor elicits an enzymatic antioxidant response to oxidative stress, ameliorates glucose and lipid dysmetabolism, and stimulates autophagy.
Export Options
About this article
Cite this article as:
Targeting PPARalpha in Alzheimer's Disease, Current Alzheimer Research 2018; 15 (4) . https://dx.doi.org/10.2174/1567205014666170505094549
DOI https://dx.doi.org/10.2174/1567205014666170505094549 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Reconceptualizing Adult Neurogenesis: Role for Sphingosine-1-Phosphate and Fibroblast Growth Factor-1 in Co-Ordinating Astrocyte-Neuronal Precursor Interactions
CNS & Neurological Disorders - Drug Targets Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?
Current Medicinal Chemistry Dietary and Plant Polyphenols Exert Neuroprotective Effects and Improve Cognitive Function in Cerebral Ischemia
Recent Patents on Food, Nutrition & Agriculture Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Endogenous Regulators of Adult CNS Neurogenesis
Current Pharmaceutical Design Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Current Pharmaceutical Design Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography
Current Medicinal Chemistry Assessment In Vitro of a Novel Therapeutic Strategy for Glioma, Combining Herpes Simplex Virus HSV1716-mediated Oncolysis with Gene Transfer and Targeted Radiotherapy
Medicinal Chemistry Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals 2,4-Thiazolidinedione as Precursor to the Synthesis of Compounds with Anti-glioma Activities in C6 and GL261 Cells
Medicinal Chemistry Boronated Compounds for Imaging Guided BNCT Applications
Anti-Cancer Agents in Medicinal Chemistry Dendrimers As Vectors for Genetic Material Delivery to the Nervous System
Current Medicinal Chemistry Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery